Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
March 31, 2020

GigaGen works on recombinant polyclonal antibody against Covid-19

GigaGen is working on a recombinant polyclonal antibody, recombinant anti-coronavirus 19 hyperimmune gammaglobulin (rCIG), as a Covid-19 treatment.

The therapy reproduces whole antibody repertoires of recovered patients, including antibodies that block further replication of the novel coronavirus.

GigaGen will formulate the antibody for intravenous administration to deliver passive immunity.

Read the full article here

Related Companies

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU